利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

38 条记录 (耗时 0.021 秒)

    TREATMENT OF AUTISM SPECTRUM DISORDERS WITH CILIARY NEUROTROPHIC FACTOR PEPTIDE MIMETIC
    2.
    发明申请
    TREATMENT OF AUTISM SPECTRUM DISORDERS WITH CILIARY NEUROTROPHIC FACTOR PEPTIDE MIMETIC 有权
    治疗急性神经营养因子胶原蛋白

    公开(公告)号：US20160143993A1

    公开(公告)日：2016-05-26

    申请号：US14950569

    申请日：2015-11-24

    申请人： The Research Foundation for Mental Hygiene, Inc.

    发明人： Khalid Iqbal ,  Inge Grundke-Iqbal

    IPC分类号： A61K38/18 ,  A61K9/00

    CPC分类号： A61K38/185

    摘要： A method of treating autism spectrum disorders using a therapeutic amount of a synthetic amino acid sequence corresponding to a portion of human ciliary neurotrophic factor (CNTF). In particular, the synthetic amino acid sequence is VGDGGLFEKKL (SEQ ID NO: 1), referred to as Peptide 6. Peptide 6 was tested and shown to exert a neuroprotective effect by modulating CNTF/JAK/STAT pathway and LIF signaling and enhancing brain derived neurotrophic factor (BDNF) expression.

    摘要翻译： 使用治疗量的对应于人睫状神经营养因子（CNTF）的一部分的合成氨基酸序列治疗自闭症谱系障碍的方法。 特别地，合成氨基酸序列是VGDGGLFEKKL（SEQ ID NO：1），被称为肽6.肽6被测试并显示出通过调节CNTF / JAK / STAT途径和LIF信号传导并增强脑源性的神经保护作用 神经营养因子（BDNF）表达。

    INTRANASAL INSULIN ADMINISTRATION FOR THE PREVENTION OF ANESTHESIA-INDUCED TAU PATHOLOGY/TAUOPATHIES
    3.
    发明申请
    INTRANASAL INSULIN ADMINISTRATION FOR THE PREVENTION OF ANESTHESIA-INDUCED TAU PATHOLOGY/TAUOPATHIES 有权
    用于预防麻醉诱导性脑病/脑病的胰岛素胰岛素管理

    公开(公告)号：US20150258178A1

    公开(公告)日：2015-09-17

    申请号：US14656975

    申请日：2015-03-13

    申请人： The Research Foundation for Mental Hygiene, Inc.

    发明人： Cheng-Xin Gong

    IPC分类号： A61K38/28

    CPC分类号： A61K38/28 ,  A61K9/0043

    摘要： Intranasal administration of insulin for a predetermined period prior to anesthesia significantly prevented anesthesia-induced tau hyperphosphorylation and cognitive impairment and enhanced brain insulin signaling in mice. Intranasal insulin thus provides a treatment for prevention of anesthesia-induced tau pathology and increased risk for tauopathies in surgical patients and may be administered to a subject prior to anesthesia, such as by administering several doses of intranasal insulin for several consecutive days prior to any anesthesia.

    摘要翻译： 在麻醉之前预定时间段内胰岛素的鼻内给药显着地阻止了麻醉引起的tau高磷酸化和认知障碍以及增强的小鼠中的脑胰岛素信号。 因此，鼻内胰岛素提供了用于预防麻醉诱发的tau病理学和增加手术患者的tau蛋白病风险的治疗，并且可以在麻醉之前向受试者施用，例如在任何麻醉之前连续数天施用若干剂量的鼻内胰岛素 。

    Neurotrophic peptides
    4.
    发明授权
    Neurotrophic peptides 有权
    神经营养肽

    公开(公告)号：US08796215B2

    公开(公告)日：2014-08-05

    申请号：US13676649

    申请日：2012-11-14

    申请人： The Research Foundation for Mental Hygiene, Inc.

    发明人： Khalid Iqbal ,  Inge Grundke-Iqbal

    IPC分类号： A01N37/18 ,  A61K38/00

    CPC分类号： C07K5/1021 ,  A61K38/08 ,  A61K38/185 ,  C07K5/1008 ,  C07K5/101 ,  C07K7/06 ,  C07K14/475

    摘要： The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO: 1) and alternatively comprising an adamantyl group at the C-and/or N-terminal end. The neurotrophic peptide can rescue cognition, correct impairments in neural cell proliferation and synaptic plasticity, and thus address the cognitive defects associated with Alzheimer's disease.

    摘要翻译： 本发明涉及具有VGDGGLFEKKL（SEQ ID NO：1）氨基酸序列的神经营养肽，或者在C-和/或N-末端含有金刚烷基。 神经营养肽可以促进神经细胞增殖和突触可塑性的认知，正确的损伤，从而解决与阿尔茨海默病有关的认知缺陷。

    SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS
    8.
    发明申请
    SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS 审中-公开

    公开(公告)号：US20190127801A1

    公开(公告)日：2019-05-02

    申请号：US16240968

    申请日：2019-01-07

    申请人： The Research Foundation For Mental Hygiene, Inc.

    发明人： James D. Clelland ,  Catherine L. Clelland

    IPC分类号： C12Q1/6883 ,  A61K33/00 ,  A61K31/5415 ,  A61K31/7052 ,  A61K31/519 ,  A61K33/14 ,  G01N33/50 ,  C12Q1/68 ,  A61K45/06

    摘要： An assay for a GCH1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the GCH1 gene, alone or in conjunction with a measurement of low or altered biopterin, or altered BH4 system measures, is used to screen or diagnose subjects at risk for developing a psychiatric, neuropsychiatric, or neurological disorder. The genetic assay, with or without a biopterin or BH4 system assay, may also be used to determine treatment regimens. For subjects with an impaired BH4 system, treatments to increase or normalize biopterin, BH4, or the BH4 system can also be used, such as BH4 supplementation, lithium treatment, phenylalanine treatment, or other treatments and therapies.

    TREATMENT OF TAUOPATHIES WITH mGluR5 ANTAGONISTS
    9.
    发明申请
    TREATMENT OF TAUOPATHIES WITH mGluR5 ANTAGONISTS 审中-公开
    用mGluR5拮抗剂治疗TAUOPATHIES

    公开(公告)号：US20160038471A1

    公开(公告)日：2016-02-11

    申请号：US14818515

    申请日：2015-08-05

    申请人： The Research Foundation for Mental Hygiene, Inc.

    发明人： Khalid Iqbal

    IPC分类号： A61K31/44 ,  A61K9/00

    CPC分类号： A61K31/44 ,  A61P25/28

    摘要： The treatment of abnormal hyperphosphorylation of tau in brains of patients with metabotropic glutamate receptor 5 (mGluR5) antagonists. The treatment uses the signaling pathway in which the inhibition of protein phosphatase 2A (PP2A) through phosphorylation of its catalytic subunit PP2Ac at Tyr307 is induced by the activation of metabotropic glutamate receptor 5 (mGluR5) and leads to hyperphosphorylation of tau. The mGluR5-PP2A axis has a central role in neurofibrillary degeneration and thus is be a therapeutic target for the treatment of tauopathies.

    摘要翻译： 治疗代谢型谷氨酸受体5（mGluR5）拮抗剂患者脑中tau异常高度磷酸化的治疗。 该治疗使用信号通路，其中通过磷酸化其催化亚基PP2Ac在Tyr307处的蛋白磷酸酶2A（PP2A）的诱导是通过代谢型谷氨酸受体5（mGluR5）的活化诱导的，并导致tau的过度磷酸化。 mGluR5-PP2A轴在神经原纤维变性中具有中心作用，因此是治疗tau蛋白病的治疗靶点。

    O-GLCNACYLATION TREATMENT FOR ISCHEMIC BRAIN INJURY
    10.
    发明申请
    O-GLCNACYLATION TREATMENT FOR ISCHEMIC BRAIN INJURY 审中-公开
    异位脑损伤的O-GLCNACYLATION治疗

    公开(公告)号：US20160022714A1

    公开(公告)日：2016-01-28

    申请号：US14808359

    申请日：2015-07-24

    申请人： THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC.

    发明人： Cheng-Xin Gong

    IPC分类号： A61K31/7008 ,  A61K31/437 ,  A61K9/00 ,  A61K31/429

    CPC分类号： A61K31/7008 ,  A61K31/429 ,  A61K31/437 ,  A61K31/7042

    摘要： Cerebral ischemia-reperfusion injury may be treated by compounds that increase brain O-GlcNAcylation, such as a therapeutic amount of a compound that increases the hexosamine biosynthesis pathway flux that bypasses glutamine/fructose-6-phosphate amidotransferase 2 or a therapeutic amount of a compound that inhibits OGA. The initial and transient elevation of brain O-GlcNAcylation is neuroprotective and helps ameliorate cerebral ischemia-reperfusion injury when administered within three hours of the ischemia-reperfusion-induced brain injury and continues for at least two days.

    摘要翻译： 可以通过增加脑O-GlcNAcylation的化合物治疗脑缺血再灌注损伤，例如治疗量的增加旁路谷氨酰胺/果糖-6-磷酸转氨酶2的己糖胺生物合成途径通量的化合物或治疗量的化合物 抑制OGA。 大脑O-GlcNAcylation的初始和瞬时升高是神经保护的，并且在缺血再灌注诱导的脑损伤的三小时内施用时有助于改善脑缺血再灌注损伤，并持续至少两天。